Clinical Trial: A Study to Evaluate the, Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07409246) titled 'A Study to Evaluate the, Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)' on Feb. 09.

Brief Summary: Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety tolerability and how ABBV-438 moves through the body, in adult participants with relapsed/refractory (R/R) MM. Adverse events tolerability, how ABBV-438 moves through the body will be assessed.

ABBV-438 is an investigational drug being developed for the treat...